Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average - What's Next?

Key Points

• Shares passed above its 50‑day moving average: Spero traded as high as $2.80 versus a 50‑day MA of $2.42 and last traded at $2.64 on volume of 694,473 shares, although the stock is reported down about 5%.
• Earnings beat but analyst sentiment mixed: Spero posted $0.53 EPS and $41.3M revenue, well above estimates, yet analysts remain divided (one upgrade to "strong‑buy," one "sell") and the MarketBeat consensus is "Reduce" with sell‑side forecasts around -1.2 EPS for the year.
• Insider selling and notable institutional activity: Insider Esther Rajavelu sold 87,917 shares (a ~7.99% reduction in her stake); insiders own 5.5% and institutions 25.6%, while GSK bought a new position valued at about $21.4M.

Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) shares passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.42 and traded as high as $2.80. Spero Therapeutics shares last traded at $2.64, with a volume of 694,473 shares.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Spero Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Sunday, March 29th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Spero Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Spero Therapeutics presently has a consensus rating of "Reduce".

Spero Therapeutics Stock Down 5.0%

The business has a fifty day simple moving average of $2.42 and a 200-day simple moving average of $2.36. The firm has a market cap of $152.83 million, a P/E ratio of 22.00 and a beta of 1.45.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported $0.53 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.20) by $0.73. The business had revenue of $41.30 million during the quarter, compared to the consensus estimate of $26.00 million. Spero Therapeutics had a return on equity of 22.53% and a net margin of 12.83%. On average, sell-side analysts anticipate that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Insider Buying and Selling at Spero Therapeutics

In other news, insider Esther Rajavelu sold 87,917 shares of the firm's stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.36, for a total transaction of $207,484.12. Following the completion of the transaction, the insider directly owned 1,012,091 shares in the company, valued at $2,388,534.76. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Spero Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. GSK plc bought a new position in shares of Spero Therapeutics during the fourth quarter valued at $21,414,000. Vanguard Group Inc. increased its holdings in shares of Spero Therapeutics by 2.0% during the third quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company's stock valued at $3,741,000 after acquiring an additional 39,474 shares in the last quarter. State Street Corp increased its holdings in shares of Spero Therapeutics by 10.1% during the fourth quarter. State Street Corp now owns 210,151 shares of the company's stock valued at $490,000 after acquiring an additional 19,200 shares in the last quarter. Ionic Capital Management LLC increased its holdings in shares of Spero Therapeutics by 39.2% during the third quarter. Ionic Capital Management LLC now owns 208,725 shares of the company's stock valued at $392,000 after acquiring an additional 58,725 shares in the last quarter. Finally, Intrepid Family Office LLC increased its holdings in shares of Spero Therapeutics by 50.0% during the fourth quarter. Intrepid Family Office LLC now owns 165,000 shares of the company's stock valued at $384,000 after acquiring an additional 55,000 shares in the last quarter. 25.60% of the stock is currently owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.